Adverse Drug Event Clinical Trial
Official title:
Over-the-counter (OTC) Labels for Older Adults
Verified date | April 2024 |
Source | Michigan State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Optimizing OTC labels for older adults: Empirical evaluation of labels designed to provide older users the information they need to to minimize adverse drug events
Status | Completed |
Enrollment | 420 |
Est. completion date | December 16, 2023 |
Est. primary completion date | December 16, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 65 Years to 110 Years |
Eligibility | Inclusion Criteria: - participant must be 65+ - participant must be legally sighted - participant must be able purchase and administer their own medications - participant must be able to perform consent without assistance. Exclusion Criteria: - if the participant has history of seizures - if the participant has impaired memory |
Country | Name | City | State |
---|---|---|---|
United States | Michigan State University | East Lansing | Michigan |
Lead Sponsor | Collaborator |
---|---|
Michigan State University | University of Wisconsin, Madison |
United States,
Becker MW, Kashy DA, Harben A, Venkatesan K, Rodriguez A, Kebede M, Martin B, Breslow R, Bix L. A novel strategy to optimize critical information on over the counter labels for older adults. Health Sci Rep. 2023 Jan 25;6(1):e1062. doi: 10.1002/hsr2.1062. — View Citation
Harben AL, Kashy DA, Esfahanian S, Liu L, Bix L, Becker MW. Using change detection to objectively evaluate whether novel over-the-counter drug labels can increase attention to critical health information among older adults. Cogn Res Princ Implic. 2021 May — View Citation
Martin BA, Breslow RM, Sims A, Harben AL, Bix L, Becker MW. Identifying over-the-counter information to prioritize for the purpose of reducing adverse drug reactions in older adults: A national survey of pharmacists. J Am Pharm Assoc (2003). 2022 Jan-Feb; — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change Detection in Over the Counter Medicine Labels | Looks at differences between two sets of images of medicine labels and locates the change between two sets of labels. | 60 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03638726 -
Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
|
Phase 4 | |
Completed |
NCT05007041 -
Simultaneous RZV and aIIV4 Vaccination
|
Phase 4 | |
Suspended |
NCT02559960 -
Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
|
||
Completed |
NCT05266300 -
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
|
||
Completed |
NCT03112083 -
Safety and Tolerability of Krill Powder Supplement in Slightly Overweight People With Moderately Elevated Blood Pressure
|
N/A | |
Completed |
NCT05028361 -
Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
|
Phase 4 | |
Completed |
NCT04284553 -
Optimizing Electronic Health Record Prompts With Behavioral Economics to Improve Prescribing for Older Adults
|
N/A | |
Recruiting |
NCT06120712 -
A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002)
|
Phase 1/Phase 2 | |
Completed |
NCT04181775 -
Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)
|
||
Completed |
NCT02906657 -
Medication Reconciliation Using Electronic Pharmaceutical Record: A Multicenter Study in the Hospitalized Elderly
|
N/A | |
Completed |
NCT03640273 -
Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients
|
Phase 2 | |
Completed |
NCT02162147 -
How Safe Are Our Pediatric Emergency Departments?
|
N/A | |
Completed |
NCT01897870 -
The Effect of a Pharmacist Home Visit on Drug-related Problems Post-discharge.
|
N/A | |
Completed |
NCT03725046 -
Impact of an Optimized Communication on the Readmission for Adverse Drug Event
|
N/A | |
Recruiting |
NCT04635956 -
Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas
|
Phase 2 | |
Active, not recruiting |
NCT05538065 -
NUDGE-EHR Replication Trial at Mass General Brigham
|
N/A | |
Completed |
NCT03442010 -
Adverse Drug Events at Emergency Department
|
||
Recruiting |
NCT04791150 -
Rheumatologic Adverse Events and Cancer Immunotherapy
|
N/A | |
Completed |
NCT02864030 -
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
|
Phase 4 | |
Completed |
NCT03665402 -
A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status
|
N/A |